iShares Nasdaq Biotech ETF (IBB)
Total Assets Under Management: $4 billion
Expense Ratio: 0.48%
One biotech ETF worth your consideration is the iShares Nasdaq Biotech ETF (IBB). This fund has been around for more than a decade and has ample assets under management of $4 billion.
IBB is a pretty pure play on biotech stocks. Nearly 80% of the 120 holdings of iShares Nasdaq Biotech ETF are straight biotech stocks — and big ones at that. The average market cap for companies this biotech ETF? $13 billion.
Top holdings of the iShares Nasdaq Biotech ETF include big biotech stocks like Biogen (BIIB) and Celgene (CELG) with nearly 9% slices each. Behind them are Gilead Sciences (GILD) at 8.5% and Amgen (AMGN) at 8.1%.
This biotech ETF gives you big-name exposure to the sector at a reasonable expense ratio of 0.48%, or $48 annually for every $10,000 invested.